TAO Synergies Inc.
TAOX | NASDAQ
$4.49
-$0.31 (-6.46%)
At close: Sep 22, 2026, 4:00 PM ET
$4.59
+$0.10 (+2.23%)
After-hours:
Sep 22, 2026, 7:44 PM ET
Company Profile
TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neurodegenerative and cognitive disorders. Beyond its drug development efforts, the firm is also diversifying its treasury strategy, with a new approach centered on the management of digital assets, primarily focusing on the acquisition and 'staking' of TAO cryptocurrency.
Key Executives
| Name | Position |
|---|---|
| Robert Weinstein | Chief Financial Officer, Executive Vice President, Treasurer & Secretary |
| Alan J. Tuchman | Chief Medical Officer |
| Joshua N. Silverman | Executive Chairman of the Board |
TAO Synergies Inc.
| Country | United States |
| IPO Date | Jul 1, 2025 |
| Industry | Software - Application |
| Sector | Technology |
| Employees | 5 |
| CEO | Joshua N. Silverman |
Contact Details
1185 Avenue of the Americas, 3rd Floor New York,
New York 10036 United States
Stock Details
| Ticker Symbol | TAOX |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001571934 |
| CUSIP Number | 87167T300 |
| ISIN Number | US87167T3005 |
| SIC Code | n/a |
Add to Watchlist
Select watchlists to add or remove TAOX